WO2025233837 - 4H-PYRIMIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR USE AS NLRP3 INFLAMMASOME INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDER
National phase entry is expected:
Publication Number
WO/2025/233837
Publication Date
13.11.2025
International Application No.
PCT/IB2025/054740
International Filing Date
06.05.2025
Title **
[English]
4H-PYRIMIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR USE AS NLRP3 INFLAMMASOME INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDER
[French]
DÉRIVÉS DE 4H-PYRIMIDO[1,2-A]PYRIMIDIN-4-ONE DESTINÉS À ÊTRE UTILISÉS EN TANT QU'INHIBITEURS DE L'INFLAMMASOME NLRP3 POUR LE TRAITEMENT D'UN TROUBLE NEURODÉGÉNÉRATIF
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
MIKAMI, Satoshi
HASUI, Tomoaki
TOYOFUKU, Masashi
TANAKA, Yuta
KAMEI, Taku
IMAMURA, Keisuke
KIKUCHI, Fumiaki
MORIMOTO, Shinji
YAMAGUCHI, Fumie
WANG, Chunxiang
TOITA, Akinori
KAKEI, Hiroyuki
NAKAMURA, Minoru
HIDAKA, Kosuke
SUGIMOTO, Takahiro
YOSHIKAWA, Masato
KAMATA, Makoto
HOMMA, Misaki
OGURO, Yuya
Priority Data
63/643,589
07.05.2024
US
63/703,505
04.10.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3590 | |
| EPO | Filing, Examination, Granting | 22407 | |
| Japan | Filing, Examination, Granting | 2837 | |
| South Korea | Filing, Examination, Granting | 3363 | |
| USA | Filing, Examination, Granting | 15440 |
Total:
47,637
Contact Us
Abstract[English]
) are as defined in the specification, for treatment of a disease, disorder or condition associated with NLRP3, including a disease, disorder or condition associated with a heterozygous gain of function mutation in the NLRP3 gene such as cryopyrin-associated periodic syndrome (CAPS).[French]
) sont tels que définis dans la description, pour le traitement d'une maladie, d'un trouble ou d'un état associé à NLRP3, y compris une maladie, un trouble ou un état associé à un gain hétérozygote de mutation de fonction dans le gène NLRP3 tel que le syndrome périodique associé à la cryopyrine (CAPS).